MétaCan
Menu
← Back to cohort
Record W4393386913 · doi:10.3390/curroncol31040141

Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

2024· article· en· W4393386913 on OpenAlexafffundvenueabout
Pam Takhar, Marc Geirnaert, Scott Gavura, Jaclyn Beca, Rebecca E. Mercer, Avram Denburg, Caroline Muñoz, Mina Tadrous, Ambica Parmar, François Dionne, Darryl Boehm, Carole Chambers, Erica H. Craig, Maureen Trudeau, Matthew C. Cheung, Joanne Houlihan, Valerie McDonald, Petros Pechlivanoglou, Marianne Taylor, Eric Wasylenko, Wiesława Dominika Wranik, Kelvin Chan

Bibliographic record

VenueCurrent Oncology · 2024
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsDalhousie UniversityUniversity of CalgaryUniversity of AlbertaInstitute for Clinical Evaluative SciencesWomen's College HospitalNova Scotia Health AuthorityUniversity of TorontoCancer Care OntarioHospital for Sick ChildrenCancerCare ManitobaSaskatchewan Cancer AgencyHealth Sciences CentreCanadian Centre for Applied Research in Cancer ControlKelowna General HospitalSunnybrook Health Science CentreSickKids FoundationAlberta Health Services
FundersCanadian Institutes of Health ResearchCanadian Centre for Applied Research in Cancer Control
KeywordsMultiple-criteria decision analysisDeliberationMedicineDecision analysisHealth technologyMultidisciplinary approachFacilitatorManagement scienceRisk analysis (engineering)Process managementOperations researchHealth careBusinessEngineering

Abstract

fetched live from OpenAlex

Multi-criteria decision analysis (MCDA) is a value assessment tool designed to help support complex decision-making by incorporating multiple factors and perspectives in a transparent, structured approach. We developed an MCDA rating tool, consisting of seven criteria evaluating the importance and feasibility of conducting potential real-world evidence (RWE) studies aimed at addressing uncertainties stemming from initial cancer drug funding recommendations. In collaboration with the Canadian Agency for Drugs and Technologies in Health's Provincial Advisory Group, a validation exercise was conducted to further evaluate the application of the rating tool using RWE proposals varying in complexity. Through this exercise, we aimed to gain insight into consensus building and deliberation processes and to identify efficiencies in the application of the rating tool. An experienced facilitator led a multidisciplinary committee, consisting of 11 Canadian experts, through consensus building, deliberation, and prioritization. A total of nine RWE proposals were evaluated and prioritized as low (n = 4), medium (n = 3), or high (n = 2) priority. Through an iterative process, efficiencies and recommendations to improve the rating tool and associated procedures were identified. The refined MCDA rating tool can help decision-makers prioritize important and feasible RWE studies for research and can enable the use of RWE for the life-cycle evaluation of cancer drugs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.241
metaresearch head score (Gemma)0.302
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.941
Threshold uncertainty score0.936

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.2410.302
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0130.014
Science and technology studies0.0060.005
Scholarly communication0.0130.003
Open science0.0040.008
Research integrity0.0030.005
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.625
GPT teacher head0.636
Teacher spread0.011 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2024
Admission routes4
Has abstractyes

Explore more

Same venueCurrent Oncology→Same topicHealth Systems, Economic Evaluations, Quality of Life→French-language works237,207→